Phase 2 Trial Results (48 Weeks) The Phase 2 trial randomized 338 adults with obesity (BMI 30) or overweight with at least one weight-related condition to retatrutide or placebo for 48 weeks (Jastreboff et al., NEJM 2023)
Common adverse effects include piloerection (goosebumps) and urinary retention, and the drug is contraindicated in patients with acute kidney failure
If semaglutide is discontinued, weight regain is possible, so ongoing medical guidance and healthy habits are essential for long-term success
TransRe undertakes no obligations to revise or update any statements, whether as a result of new information, future events or otherwise, and in no event shall TransRe or any of its affiliates or employees be liable for any damage or loss arising in connection with the use of the information relating to this document
Compared to Matrixyl 3000, GHK-Cu produced a 31.6% reduction of wrinkle volume
Fiber does not need to arrive as a huge salad